Differential functional selectivity and downstream signaling bias of ghrelin receptor antagonists and inverse agonists
- PMID:30020830
- DOI: 10.1096/fj.201800655R
Differential functional selectivity and downstream signaling bias of ghrelin receptor antagonists and inverse agonists
Abstract
The ghrelin receptor [growth hormone secretagogue receptor (GHSR)-1a] represents a promising pharmacologic target for the treatment of metabolic disorders, including obesity and cachexia, via central appetite modulation. The GHSR-1a has a complex pharmacology, highlighted by G-protein-dependent and -independent downstream signaling pathways and high basal constitutive activity. The functional selectivity and signaling bias of many GHSR-1a-specific ligands has not been fully characterized. In this study, we investigated the pharmacologic properties of ghrelin, MK-0677, L692,585, and [d-Lys3]-growth hormone-releasing peptide-6 (Dlys), JMV2959, and [d-Arg(1),d-Phe(5),d-Trp(7, 9),Leu(11)]-substance P (SP-analog). We investigated their effect on basal GHSR-1a constitutive signaling, ligand-directed downstream GHSR-1a signaling, functional selectivity, and signaling bias. Dlys behaved as a partial antagonist with a strong bias toward GHSR-1a-β-arrestin signaling, whereas JMV2959 acted as a full unbiased GHSR-1a antagonist. Moreover, the SP-analog behaved as an inverse agonist increasing G-protein-dependent signaling, but only at high concentrations, whereas, at low concentrations, the SP-analog attenuated β-arrestin-dependent signaling. Considering the limited success in the clinical development of GHSR-1a-targeted drugs so far, these findings provide a novel insight into the pharmacologic characteristics of GHSR-1a ligands and their signaling bias, which has important implications in the design of novel, more selective GHSR-1a ligands with predictable functional outcome and selectivity for preclinical and clinical drug development.-Ramirez, V. T., van Oeffelen, W. E. P. A., Torres-Fuentes, C., Chruścicka, B., Druelle, C., Golubeva, A. V., van de Wouw, M., Dinan, T. G., Cryan, J. F., Schellekens, H. Differential functional selectivity and downstream signaling bias of ghrelin receptor antagonists and inverse agonists.
Keywords: GHSR-1a; GPCR; probe of dependence.
Similar articles
- In vitro pharmacological characterization of growth hormone secretagogue receptor ligands using the dynamic mass redistribution and calcium mobilization assays.Sturaro C, Ruzza C, Ferrari F, Pola P, Argentieri M, Frezza A, Marzola E, Bettegazzi B, Cattaneo S, Pietra C, Malfacini D, Calò G.Sturaro C, et al.Eur J Pharmacol. 2024 Oct 15;981:176880. doi: 10.1016/j.ejphar.2024.176880. Epub 2024 Aug 10.Eur J Pharmacol. 2024.PMID:39128804
- Short-chain fatty acids and microbiota metabolites attenuate ghrelin receptor signaling.Torres-Fuentes C, Golubeva AV, Zhdanov AV, Wallace S, Arboleya S, Papkovsky DB, Aidy SE, Ross P, Roy BL, Stanton C, Dinan TG, Cryan JF, Schellekens H.Torres-Fuentes C, et al.FASEB J. 2019 Dec;33(12):13546-13559. doi: 10.1096/fj.201901433R. Epub 2019 Oct 9.FASEB J. 2019.PMID:31545915
- Enhanced responsiveness of Ghsr Q343X rats to ghrelin results in enhanced adiposity without increased appetite.Chebani Y, Marion C, Zizzari P, Chettab K, Pastor M, Korostelev M, Geny D, Epelbaum J, Tolle V, Morisset-Lopez S, Pantel J.Chebani Y, et al.Sci Signal. 2016 Apr 19;9(424):ra39. doi: 10.1126/scisignal.aae0374.Sci Signal. 2016.PMID:27095593
- Therapeutic potential of GHSR-1A antagonism in alcohol dependence, a review.Gupta S, Mukhopadhyay S, Mitra A.Gupta S, et al.Life Sci. 2022 Feb 15;291:120316. doi: 10.1016/j.lfs.2022.120316. Epub 2022 Jan 10.Life Sci. 2022.PMID:35016882Review.
- THE INTRIGUING LIGAND-DEPENDENT AND LIGAND-INDEPENDENT ACTIONS OF THE GROWTH HORMONE SECRETAGOGUE RECEPTOR ON REWARD-RELATED BEHAVIORS.Cornejo MP, Mustafá ER, Barrile F, Cassano D, De Francesco PN, Raingo J, Perello M.Cornejo MP, et al.Neurosci Biobehav Rev. 2021 Jan;120:401-416. doi: 10.1016/j.neubiorev.2020.10.017. Epub 2020 Nov 4.Neurosci Biobehav Rev. 2021.PMID:33157147Review.
Cited by
- Ghrelin Based Therapy of Metabolic Diseases.Liang Y, Yin W, Yin Y, Zhang W.Liang Y, et al.Curr Med Chem. 2021;28(13):2565-2576. doi: 10.2174/0929867327666200615152804.Curr Med Chem. 2021.PMID:32538716Free PMC article.Review.
- Ghrelin in Depression: A Promising Therapeutic Target.Kore MS, Mamsa R, Patil D, Bhatt LK.Kore MS, et al.Mol Neurobiol. 2025 Apr;62(4):4237-4249. doi: 10.1007/s12035-024-04554-1. Epub 2024 Oct 18.Mol Neurobiol. 2025.PMID:39424690Review.
- Pharmacological Modulation of Ghrelin to Induce Weight Loss: Successes and Challenges.Schalla MA, Stengel A.Schalla MA, et al.Curr Diab Rep. 2019 Sep 10;19(10):102. doi: 10.1007/s11892-019-1211-9.Curr Diab Rep. 2019.PMID:31506846Review.
- Ghrelin signaling in the cerebellar cortex enhances GABAergic transmission onto Purkinje cells.Hirono M, Nakata M.Hirono M, et al.Sci Rep. 2023 Feb 7;13(1):2150. doi: 10.1038/s41598-023-29226-3.Sci Rep. 2023.PMID:36750743Free PMC article.
- Ghrelin receptor antagonist JMV2959 blunts cocaine and oxycodone drug-seeking, but not self-administration, in male rats.Merritt CR, Garcia EJ, Brehm VD, Fox RG, Moeller FG, Anastasio NC, Cunningham KA.Merritt CR, et al.Front Pharmacol. 2023 Sep 19;14:1268366. doi: 10.3389/fphar.2023.1268366. eCollection 2023.Front Pharmacol. 2023.PMID:37795028Free PMC article.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources